A Case of Non-Small Cell Lung Cancer with Possible “Disease Flare” on Nivolumab Treatment

Background. Recent clinical trials proven the clinically significant efficacy and tolerability of nivolumab, a programmed death 1 (PD-1) inhibitor, in previously treated patients with non-small cell lung cancer (NSCLC). Case Presentation. Here, we describe the case of a patient who experienced possi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chubachi, Shotaro, Yasuda, Hiroyuki, Irie, Hidehiro, Fukunaga, Koichi, Naoki, Katsuhiko, Soejima, Kenzo, Betsuyaku, Tomoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223009/
https://www.ncbi.nlm.nih.gov/pubmed/28116195
http://dx.doi.org/10.1155/2016/1075641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223009/
https://www.ncbi.nlm.nih.gov/pubmed/28116195
http://dx.doi.org/10.1155/2016/1075641

Ejemplares similares